GPC3 / Glypican-3 · Western blot design guide

Design a Western Blot for GPC3

Real validated GPC3 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-GPC3 WB antibodies. Everything you need to plan the experiment before you commit precious samples.

Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use

Western blot protocol sheet for GPC3: expected band ~65.6 kDa, hero antibody A01922, catalog values and labelled standard workflow; separate PMC comparisons on the guide — Printable **GPC3** Western blot protocol sheet — expected band ~65.6 kDa, antibody A01922, controls and PMC citations. Open the full GPC3 WB guide →

Navigate to: Protocols Band Controls Antibodies

GPC3 Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running

	Expected band	~65.6 kDa
	Gel	12–15% (standard starting point)
	Negative control ⓘ	Suggested KO / knockdown lysate

Important caveats

Reasons your observed band may differ from the expected size.

	PTM	Glycosylated + Phosphorylated
	Caveat	Processing-state controls
	Gene-set association	MSigDB Hallmark membership
	Isoform	3 isoform(s)

Section 1

Real Curated GPC3 Western Blot Protocols

The A01922 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.

Recommended Western blot protocol parameters
Sample / lysate	HepG2 cells (catalog A01922)
Gel %	12–15% (standard starting point)
Load	20–30 µg total protein per lane; optimize for abundance (standard starting point)
Transfer	Standard semi-dry transfer; verify efficiency (standard starting point)
Membrane	0.45 µm PVDF (standard starting point)
Blocking	5% milk or 5% BSA in TBST (standard starting point)
Primary antibody	A01922; use the WB datasheet starting dilution (standard starting point)
Primary incubation	Overnight at 4 °C (standard starting point)
Secondary antibody	1:20000 (catalog A01922)
Secondary incubation	1 h at room temperature (standard starting point)
Wash	3 × 5 min in TBST (standard starting point)
Detection	ECL; bracket exposures to avoid saturation (standard starting point)

Section 2

What Is the Expected GPC3 Western Blot Band Size?

GPC3 has a predicted 65.6 kDa precursor; glycosylation and processing may affect migration, but no empirical band position or feature-specific shift is established.

What am I looking at on my blot?
Band near 65.6 kDa	Compatible with the predicted GPC3 precursor; confirm identity with antibody controls.
Slower or diffuse band	May reflect N-linked glycans or glycosaminoglycans; the sites alone do not establish a visible shift.
Bands below the precursor	May represent processed alpha or beta chains after furin-like cleavage; fragment masses are unspecified.
Several bands	May reflect processing or isoforms 1, 2, and 3; distinct isoform bands are not established.

💡Expected GPC3 appearanceUniProt predicts a 65.6 kDa GPC3 precursor, but glycosylation, signal-peptide and propeptide removal, and cleavage can alter migration; no empirical band size is supplied, so verify band identity with antibody controls.

How each factor affects band size
65.6 kDa predicted precursor	Provides the full-length sequence mass, not a measured Western-blot position.
N-linked glycosylation at Asn124	May increase apparent size if occupied; the shift is unquantified.
N-linked glycosylation at Asn241	May increase apparent size if occupied; the shift is unquantified.
N-linked glycosylation at Asn418	May increase apparent size if occupied; the shift is unquantified.
Glycosaminoglycan attachment at Ser495 and Ser509	May increase or broaden apparent size if occupied; migration is unmeasured.
Signal peptide 1–24 and propeptide 555–580	Their removal reduces sequence mass relative to the precursor.
Disulfide-linked alpha and beta chains	Furin-like cleavage can yield smaller chains upon reduction; their masses are unspecified.
Isoforms 1, 2, and 3	Sequence differences may alter size, but relative masses and band separation are unspecified.

Why is my band missing or off?
Situation	Likely cause	Next action
No band in lysate	GPI-anchored GPC3 may be poorly recovered from the membrane fraction.	Check membrane extraction and a GPC3-positive lysate control.
Band higher than expected	N-linked glycans or glycosaminoglycans may alter migration.	Compare glycan-treated and untreated samples and confirm identity with a GPC3 control.
Band lower than expected	Signal-peptide or propeptide removal, or furin-like cleavage, may yield a smaller species.	Check the antibody epitope and compare reducing conditions with a GPC3-positive control.
Broad smear instead of sharp band	Variable glycan or glycosaminoglycan occupancy is possible.	Compare treated and untreated samples and verify specificity with a GPC3 control.
Multiple bands	Processing or isoforms 1, 2, and 3 may contribute; their separation is unconfirmed.	Check epitope coverage and compare reducing conditions and a GPC3-positive control.
Fragments below expected size	Furin-like cleavage produces disulfide-linked alpha and beta chains.	Compare reducing and nonreducing samples and check which chain the antibody recognizes.

Source: UniProt P51654 Human Protein Atlas product datasheet (A01922)

Experiment evidence

Western blot images showing GPC3 band

A01922 · GPC3

A01922-2 · GPC3

M01922-1 · GPC3

← swipe / scroll for more images →

Real WB data behind the band-size expectations in this section.

Sample controls for GPC3 Western blot

🧪For positive controls for GPC3 in Western blot, you can use a GPC3-positive sample, but the supplied HPA evidence identifies no specific tissue or cell line.

Positive control: No high/medium HPA tissue identified

Negative control: Suggested KO / knockdown lysate

Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.

⚠️Feasibility: HPA provides no validated tissue controls, and GPC3’s extracellular, GPI-anchored location may limit its signal in whole-cell lysate.

HPA tissue expression evidence for GPC3

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Higher expression tissues · candidate positive controls from IHC

Tissue	Cell type	Level	Evidence	Source
No high/medium HPA tissues identified in the supplied evidence.

Lower expression tissues · IHC evidence, not confirmed WB-negative controls

Tissue	Cell type	Level	Evidence	Source
No lower-expression tissue rows available in the supplied evidence.

Section 3

Advanced GPC3 Western Blot Tips

Deeper troubleshooting and optimisation questions for GPC3, answered from its protein features.

How should GPC3 band migration be interpreted?

Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.

Could different GPC3 isoforms produce different bands?

Isoforms · Three isoforms are listed. Isoform 2 lacks canonical residues 59–112; isoform 3 replaces canonical Thr344 with TETEKKIWHFKYPIFFLCIGLDLQ. Consider isoform expression and antibody epitope location when interpreting multiple bands. These sequence changes alone do not establish which bands will be visible.

Which GPC3 modification sites matter when interpreting a band?

PTM · UniProt lists N-linked glycosylation at Asn124, Asn241, and Asn418; glycosaminoglycan attachment at Ser495 and Ser509; pyrrolidone carboxylic acid at position 25; and FAM20C-dependent phosphorylation at Ser352. Coordinates refer to the supplied canonical sequence and may differ from antibody or paper numbering. Site annotations alone do not establish a visible shift.

Does this guide establish induction of GPC3?

Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.

How should transfer be checked for GPC3?

Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.

How should blocking be optimized?

Blocking · Standard workflow guidance: follow the A01922 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.

How should multiple GPC3 bands be quantified?

Quantitation · Define which bands the assay measures before comparing samples. GPC3 has three isoforms, glycosylation and glycosaminoglycan sites, and furin-like cleavage into disulfide-linked chains; these features permit several interpretations of a band pattern. Validate band identity with antibody epitope information before summing bands or assigning one as total GPC3.

Why might GPC3 migrate differently from its predicted 65.6 kDa mass?

Interpretation · The 65.6 kDa value is calculated from the canonical sequence. GPC3 has a signal peptide at residues 1–24, a propeptide at 555–580, three N-linked glycosylation sites, two glycosaminoglycan attachment sites, and cleavage into alpha and beta chains. These features make the calculated mass an uncertain guide to migration; no observed band size is supplied.

A furin-like convertase cleaves GPC3 into alpha and beta chains that form a disulfide-linked heterodimer. When interpreting smaller bands, consider these processed chains alongside the full-length protein. The supplied features do not give the cleavage position or expected chain masses, so do not assign a band by size alone.

GPC3 has seven annotated disulfide bonds, and its processed alpha and beta chains form a disulfide-linked heterodimer. Comparing reducing and nonreducing samples may help assess whether a band represents linked chains, but the supplied features do not predict specific band positions or guarantee a change.

GPC3 is annotated on the extracellular side of the cell membrane and has a GPI anchor. Include a membrane-containing fraction when assessing cellular GPC3, and account for fraction choice when comparing samples. The supplied features do not establish how much GPC3 appears in any particular fraction.

Boster reagents

GPC3 Western Blot Antibodies

Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.

Real WB data Western Blot analysis of HepG2 cells using Glypican-3 Polyclonal Antibody. Secondary antibody was diluted at 1:20000

Anti-Glypican-3 GPC3 Antibody

Cat # A01922

View product →

Real WB data

Western blot analysis of Glypican 3/GPC3 using anti-Glypican 3/GPC3 antibody (A01922-2). Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions. Lane 1: human HepG2 whole cell lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-Glypican 3/GPC3 antigen affinity purified polyclonal antibody (Catalog # A01922-2) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for Glypican 3/GPC3 at approximately 66 kDa. The expected band size for Glypican 3/GPC3 is at 66 kDa.

Anti-Glypican 3/GPC3 Antibody Picoband®

Cat # A01922-2

View product →

Real WB data

Western blot analysis of GPC3 using anti-GPC3 antibody (M01922-1). Electrophoresis was performed on a 10% SDS-PAGE gel at 80V (Stacking gel) / 120V (Resolving gel) for 2 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions. Lane 1: human HepG2 whole cell lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-GPC3 antigen affinity purified monoclonal antibody (M01922-1) at 1:500 overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an ECL Plus Western Blotting Substrate (Catalog # AR1196-200) with Tanon 5200 system. A specific band was detected for GPC3 at approximately 66 kDa. The expected band size for GPC3 is at 66 kDa.

Anti-Glypican 3 Monoclonal Antibody

Cat # M01922-1

View product →

All three listed anti-GPC3 antibodies have Western blot images using human HepG2 cells. A01922-2 and M01922-1 report bands near 66 kDa under reducing conditions. The supplied evidence does not establish performance in other sample types or species.

Which to pick: For human HepG2 lysate, choose A01922-2 for a documented polyclonal protocol or M01922-1 for a documented monoclonal protocol. A01922 lists mouse and rat reactivity, but its supplied Western blot image uses HepG2 cells only.

Source: BosterBio GPC3 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.

References

UniProt Consortium. UniProt entry P51654.
Human Protein Atlas. GPC3 tissue expression.
PMC6901039 — target-verified WB comparison
PMC5581077 — target-verified WB comparison
PMC11177114 — target-verified WB comparison